Summary
Cyclophosphamide pharmacolinetics have been studied in 16 female patients with advanced breast cancer. The group included 7 patients who were >20%, ≤30% over ideal body weight and 5 patients who were >30% over ideal body weight. Cyclophosphamide plasma elimination half-lives ranged between 152 and 984 min (mean 457 min), the apparent volume of distribution between 19.1 and 62.31 (mean 36.11), and plasma clearance between 25.9 and 166.6 ml/min (mean 69.5 ml/min). There was a significant positive correlation (r=0.624,P=0.010) between body weight and plasma elimination half-life, and a significant negative correlation between body weight and cyclophosphamide clearance when normalized to body surface area (r=0.578,P=0.019) or normalized to ideal body weight (r=0.531,P=0.0345). the apparent volume of distribution did not correlate with body weight. The results show that cyclophosphamide disposition is altered in patients with increased body weight.
Similar content being viewed by others
References
Abernethy DR, Greeblatt DJ (1982) Pharmacokinetics of drugs in obesity. Clin Pharmacokinet 7: 108
Abernethy DR, Greenblatt DJ (1984) Lidocaine disposition in obesity. Am J Cardiol 53: 1183
Abernethy DR, Greeblatt DJ (1985) Ibuprofen disposition in obesity. Arthritis Rheum 28: 1117
Abernethy DR, Greenblatt DJ (1986) Drug disposition in obese humans, an update. Clin Pharmacokinet 11: 199
Abernethy DR, Greenblatt DJ, Divoll M, Hermatz JS, Shader RI (1981) Alterations in drug distribution and clearance due to obesity. J Pharmacol Exp Ther 217: 681
Abernethy DR, Greenblatt DJ, Smith TW (1981) Digoxin disposition in obesity: clinical pharmacokinetic investigation. Am Heart J 102: 740
Abernethy DR, Divoll M, Greenblatt DJ, Ameer B (1982) Pharmacokinetics of drugs in obesity. Clin Pharmacol Ther 31: 783
Abernethy DR, Greenblatt DJ, Divoll M, Shader RI (1983) Enhanced glucuronide conjugation of drugs in obesity; studies of lorazepam, oxazepam, and acetaminophen. J Lab Clin Med 101: 873
Abernethy DR, Todd EL, Schwartz JB (1985) Caffeine disposition in obesity. Br J Clin Pharmacol 20: 61
Adler M, Schaffner F (1979) Fatty liver hepatitis and cirrhosis in obese patients. Am J Med 67: 811
Bagley CM, Bostick FW, DeVita VT (1973) Clinical pharmacology of cyclophosphamide. Cancer Res 33: 226
Bauer LA, Wareing-Tran C, Edwards WAD, Raisys V, Ferrer L, et al (1985) Cimetidine clearance in the obese. Clin Pharmacol Ther 37: 424
Benedek IH, Fiske WD, Griffen WO, Bell RM, Blouin RA, et al (1983) Serum alpha-1-acid glycoprotein and the binding of drugs in obesity. Br J Clin Pharmacol 16: 751
Braumwell V, Calvert RT, Edwards G, Scarffe H, Crowther D (1979) The disposition of cyclophosphamide in a group of myeloma patients. Cancer Chemother Pharmacol 3: 253
Bray GA (1979) Obesity. Disease-a-month 26 (October): 7
Brouwer KLR, Kostenbauder HB, McNamara PJ, Blouin RA (1984) Phenobarbital in the genetically obese Zucker rat: II. In vivo and in vitro assessments of microsomal enzyme inducation. J Pharmacol Exp Ther 231: 654
Christoff PD, Conti DR, Naylor C, Jusko WJ (1983) Procainamide disposition in obesity. Drug Intell Clin Pharm 17: 516
De Divitiis O, Fazio S, Pettito M, Maddalena G, Contalde F, et al (1981) Obesity and cardiac function. Circulation 64: 477
D'Incalci MD, Bolis G, Mangioni C, Morosa L, Garattini S (1978) Variable absorption of hexamethylmelamine in man. Cancer Treat Rep 62: 2117
D'Incalci MD, Beggiolin G, Sessa C, Mangioni C (1981) Influence of ascites on the pharmacokinetics of hexamethylmelamine andN-demethylated metabolites in ovarian cancer patients. Eur J Clin Oncol 12: 13331
Dionne RE, Bauer LA, Gibson GA, Griffen WO, Blouin RA (1981) Estimating creatinine clearance in morbidly obese patients. Am J Hosp Pharm 38: 841
Dorsey JL, Smith JT (1981) Comparison of hepatic cytochrome P-450 levels of obese mice and nonobese mice. Nutr Rep Int 24: 777
Forbes GB, Welle SL (1983) Lean body mass in obesity. Int J Obesity 7: 99
Gal P, Jusko WJ, Yurchak AM, Franklin BA (1978) Theophylline disposition in obesity. Clin Pharmacol Ther 23: 438
Grochow LB, Colvin M (1979) Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 4: 380
Harris RN, Basseches PJ, Appel PL, Durski AM, Powis G (1984) Carbon tetrachloride induced increase in the antitumor activity of cyclophosphamide in mice: A pharmacokinetic study. Cancer Chemother Pharmacol 12: 167
Juma F, Ogada T (1983) Pharmacokinetics of cyclophosphamide in Kenyan Africans. Br J Clin Pharmacol 16: 61
Juma FD, Rogers HJ, Trounce JR (1980) The pharmacokinetics of cyclophosphamide phosphoramide mustard and nor-nitrogen mustard studied by gas chromatography in patients receiving cyclophosphamide therapy. Br J Clin Pharmacol 10: 327
Juma FD, Rogers HJ, Trounce JR (1981) Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites. Eur J Clin Pharmacol 19: 443
Kirschner MA, Schneider G, Ertel NH, Worton E (1982) Obesity, androgens, estrogens and cancer risk. Cancer Res 42 [Suppl]: 3281s
Metzler CM, Elfring G, McEwen B (1974) A package of computer programs for pharmacokinetic modeling. Biometrics 30: 562
Milsap RL, Plaisance IL, Jusko WJ (1984) Prednisolone disposition in obese man. Clin Pharmacol Ther 36: 824
Ottolenghi L, Morasca L, Marsoni S, Piazza E, Soresi E, Libretti A, Garattini S (1980) Plasma levels of cyclophosphamide in patients under polychemotherapeutic regimens. Biomedicine 32: 123
Powis G (1983) Effects of diseases states on pharmacokinetics of anticancer drugs. In: Ames MM, Powis G, Kovach JS (eds) Pharmacokinetics of anticancer agents in humans. Elsevier, Amsterdam, p 363
Powis G (1985) Anticancer drug pharmacodynamics. Cancer Chemother Pharmacol 14: 177
Powis G, Reece PA, Ingle JM, Ahmann DL (1986) Cyclophosphamide pharmacokinetics in obese cancer patients. Acta Pharmacol Toxicol 59 [Suppl V]: 296
Ritschel WA, Bykadi G, Norman EJ, Cluxton RJ, Denton D (1981) Salivary elimination of cyclophosphamide in man. J Clin Pharmacol 21: 461
Rohrbaugh TM, Danish M, Ragni MC, Yaffe SJ (1982) The effect of obesity on apparent volume of distribution of theophylline. Pediatr Pharmacol (New York) 2: 75
Sketris I, Lesar T, Zaske DE, Cipolle RJ (1982) Effect of obesity on gentamicin pharmacokinetics. J Clin Pharmacol 21: 288
Sladek NE (1987) Oxazaphosphorines. In: Powis G, Prough R (eds) Metabolism and actions of anticancer drugs. Taylor and Francis, London, p 48
Sladek NE, Priest J, Doeden D, Mirocha CJ, Pathre S, Krivit W (1980) Plasma half-life and urinary excretion of cyclophosphamide in pediatric patients. Cancer Treat Rep 64: 1061
Wagner JG (1976) Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data. J Pharmacokinet Biopharm 4: 443
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Powis, G., Reece, P., Ahmann, D.L. et al. Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemother. Pharmacol. 20, 219–222 (1987). https://doi.org/10.1007/BF00570489
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00570489